Skip to main content
541 search results for:

Erenumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-04-2024 | Migraine | News | Article

    APPRAIS(ing) the use of erenumab in migraine prevention

    People with episodic migraine who have failed previous preventive treatments are more likely to complete a year of treatment and experience a reduction in monthly migraine days with erenumab.

  2. Open Access 01-12-2024 | Erenumab | OriginalPaper

    Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis

    Migraine is a complex neurological disorder characterised by recurrent moderate or severe headache attacks lasting 4–72 h. Individuals with episodic migraine (EM) typically experience 0–14 monthly migraine days (MMD), whereas those with chronic …

  3. 01-01-2024 | Erenumab | News

    Erenumab

    No improvement
  4. Open Access 01-12-2024 | Erenumab | OriginalPaper

    Double-blind, randomized, placebo-controlled study to evaluate erenumab-specific central effects: an fMRI study

    Migraine, originally interpreted as a vascular disorder, has undergone a profound evolution in our understanding of its pathophysiological background over the past century [ 1 , 2 ]. Historically, extracerebral (meningeal) vessels were implicated …

  5. 22-11-2023 | Erenumab | Erratum

    Correction: Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects

  6. Open Access 01-12-2023 | Erenumab | OriginalPaper

    Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany

    Migraine is a highly prevalent neurological disorder that causes significant disability over decades. Over one billion individuals suffer from migraine worldwide, often in what would have been their most economically productive years [ 1 , 2 ].

  7. Open Access 12-09-2023 | Erenumab | OriginalPaper

    Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis

    Migraine is a very common and debilitating neurological disorder with substantial impact on the affected individual and society [ 1 – 3 ]. Since 1990, migraine has increasingly been recognized as a major cause of disability worldwide [ 4 , 5 ]. In …

  8. Open Access 01-12-2023 | Erenumab | OriginalPaper

    One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study

    Targeting the pathway of calcitonin gene-related peptide (CGRP) has opened a new era for migraine treatment [ 1 ]. Thus, the prophylaxis of migraine has experienced major changes since the introduction of monoclonal antibodies (mAbs) targeting the …

  9. Open Access 08-08-2023 | Erenumab | OriginalPaper

    The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN)

    Migraine is a common and highly disabling neurological disease [ 1 ]. Increased recognition of the huge personal and social impact of migraine has increased interest in the development of new treatments. Based on evidence supporting a key role of …

  10. Open Access 01-12-2022 | Migraine | OriginalPaper

    Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE

    Migraine is a common chronic neurovascular disease associated with a significant personal burden of pain, disability, and reduced quality of life. The personal, social, and healthcare-related economic burden associated with the disease is also …

  11. 01-07-2023 | Erenumab | News

    Erenumab/ibuprofen/sumatriptan

    Treatment failure and constipation: case report
  12. 01-11-2021 | Granulomatosis with Polyangiitis | News

    Erenumab/fremanezumab/galcanezumab

    Various toxicities: 8 case reports
  13. 01-05-2023 | Gastroesophageal Reflux Disease | News

    Erenumab/fremanezumab/galcanezumab

    Various toxicities: 4 case reports
  14. 01-07-2021 | Migraine | News

    Erenumab

    Various toxicities: case report
  15. 01-04-2023 | Myasthenia Gravis | News

    Erenumab

    Ocular myasthenia gravis-like symptoms: case report
  16. 01-02-2021 | Antiepileptic Drugs | News

    Erenumab

    Brain injury manifesting as epilepsy: case report
  17. 01-04-2023 | Migraine | News

    Erenumab

    Symmetrical drug-related intertriginous and flexural exanthema: case report
  18. Open Access 01-03-2022 | Migraine | OriginalPaper

    Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine

    Migraine is globally among the leading causes of disability according to the number of years lived with disability metric [ 1 ]. This neurological disease particularly affects people in their prime working years and is not only associated with …

  19. 01-01-2021 | Hypertension | News

    Hypertension with erenumab

  20. 01-12-2022 | Migraine | News

    Erenumab

    Worsening of constipation: case report

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.